Ghanaian Researchers Spearhead International Effort to Develop Child-Friendly Ivermectin Treatment

Ghanaian scientists are leading a major international initiative to bridge a critical gap in the treatment of neglected tropical diseases (NTDs) among young children. The project, titled IVM-KIDS, is spearheaded by the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR) at the Kwame Nkrumah University of Science and Technology (KNUST). It aims to develop and test safe formulations of ivermectin specifically for children weighing under 15 kilograms, a demographic that is currently excluded from using the prescription drug due to a lack of safety data for very young ages.

The initiative addresses a long-standing public health challenge where children under five, often the most vulnerable to parasitic infections, lack access to effective treatments like ivermectin. Supported by European Union (EU) funding, the project involves a robust partnership between various African and European institutions. The research is not merely about adjusting dosage; it focuses on creating child-friendly formulations that are safe and easy to administer to infants and toddlers, potentially revolutionizing how NTDs are managed in endemic regions like Ghana.

Professor John Amuasi, a senior researcher on the project, emphasized the importance of the drug, noting that ivermectin is "a wonderful drug used to address many health issues, particularly NTDs." However, its current restriction based on weight and age limits its impact on those who often need it most. Dr. Stella Kepha added that the upcoming studies are specifically "designed to answer necessary questions to include young children in treatment programs," ensuring that public health policies can eventually be updated with rigorous, evidence-based data.

Looking ahead, the research team expects clinical trials to commence in 2027, following necessary regulatory approvals from the relevant authorities. Beyond the immediate health benefits for children, the IVM-KIDS project seeks to generate actionable evidence that will allow global health organizations and national governments to adapt their health policies. By validating the safety and efficacy of ivermectin for the youngest populations, Ghana is positioning itself at the forefront of global efforts to eradicate neglected tropical diseases and improve child health outcomes.